echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > 63 drugs will be transferred out of medical insurance

    63 drugs will be transferred out of medical insurance

    • Last Update: 2020-10-07
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    On September 14th, Shaanxi Medical Insurance Bureau issued a public notice on the transfer of some drugs out of the scope of payment of basic medical insurance in our province.
    Publicity said that in order to implement the relevant documents of the State Health Insurance Administration requirements, according to the completion of shaanxi Province's additional Class B drug digestion tasks, Shaanxi Medical Insurance Bureau combined with medical institutions clinical diagnosis and treatment practice and the habits of the insured, after expert demonstration, identified the first batch of digestive drugs list, the list of drugs will be included in the list from January 1, 2021 to remove the Shaanxi Province health insurance fund payment range.
    publicity period is from 14 September to 19 September.
    According to Cypress Blue combing, a total of 63 drugs were included in the list of the first digestive drugs in Shaanxi Province, involving aluminum hydroxide, moshapili, metformin margarine, quanneidxine, keromycin, aminophen chlorpyrithrome, amoxicillin, compound cephalosporine , pefluorosa star, curk reed clove bean, dicazepam, dosepine, tesame salbinol, ephedrine, compound licorice, axiowe, glycerine, strong cold tablets, fennel positive air drops, heating particles, cough flat breath oral solution, double red live blood capsules and so on.
    A large number of drugs have been transferred out on August 20, 2019, the State Health Insurance Administration issued the "National Health Insurance Administration of the Ministry of Human Resources and Social Security on the issuance of the National Basic Medical Insurance, Industrial Injury Insurance and Maternity Insurance Drug Catalog Notice" clearly: all localities should strictly implement the "Drug Catalog", may not make their own catalogues or use different methods to increase the catalog of drugs, nor may they adjust the limited payment scope of drugs in the catalogue.
    class B drugs added in the original provincial drug catalogue should be gradually digested within 3 years.
    the digestion process, provinces should give priority to adjusting the scope of payments for medicines that are included in the scope of national key monitoring.
    February 5, the State Health Insurance Administration issued the "2020 Health Insurance Key Points Notice" again mentioned to strengthen the management of the health insurance catalogue, strengthen supervision and dispatch, and promote local progress to complete the digestion of self-replenishing varieties.
    On June 17, the three departments of the State Health Insurance Administration issued a "Notice on doing a good job in 2020 urban and rural residents of basic medical security" clearly: the requirements for the gradual unification of the scope of payment of medical insurance drugs, the establishment of a monitoring mechanism for the implementation of negotiated drugs, the formulation of three-year digestion plan for the provinces to add varieties, by the end of June 2020 to the national key monitoring varieties out of the catalogue and complete 40% of the provincial supplements digestion.
    , from July 1st, 20 countries will focus on monitoring drugs and 40 percent of provincial supplements in the country's provinces will be transferred out of health insurance, no longer covered by health insurance reimbursement.
    According to Cypress Blue statistics, up to now, including Gansu, Ningxia, Xinjiang, Guangxi, Zhejiang, a total of more than 20 provinces have landed to implement the local update directory transfer policy - of which Yunnan, Hunan, Jilin, Tianjin, Hebei, Anhui, Tibet And other places have made clear the first batch of additional varieties of local health insurance, a large number of varieties from July 1, 2020 out of the local health insurance directory, in addition, Beijing, Ningxia, Xinjiang, Guangxi, Chongqing and other places have also announced the final adjustment and digestion time.
    According to Saibai Blue previously understood that the local additional varieties out of the medical insurance arrangements are as follows: 1, the focus of monitoring the catalog of drugs to take the lead out of the health insurance catalog;
    , according to Seber blue combing, the local supplement varieties out of the health insurance limit mainly concentrated in late June 2022.
    Although the National Health Insurance Administration requires local supplements to the varieties in the health insurance catalogue to be transferred out of the catalogue in batches within three years, it is not difficult to see that the local health insurance catalogues in the provinces are not at different pace.
    analysis points out that next year and the year after, or the provinces clean up the local health care directory for two years.
    can be said that in the next two years, the local health insurance supplement varieties of digestion and transfer will also increase efforts to carry out.
    National Health Insurance Directory into an important opportunity in addition to the local health insurance catalog of additional varieties transferred out, the new version of the National Health Insurance Directory is also expected to be introduced at the end of the year, and is expected to start from next year, the National Health Insurance Directory officially entered the normal adjustment phase.
    will be adjusted annually in principle in the future.
    According to the Interim Measures for the Administration of Essential Medical Insurance Drugs, which were officially implemented on September 1, 2020, eight categories of drugs are no longer included in the List of Medicines: 1, drugs that play a major role in tonic; Drugs for the effects of hair, weight loss, beauty, smoking cessation, alcohol withdrawal, etc.; 6, drugs that cannot be charged separately for reasons such as being included in medical treatment programs; 7, alcohol preparations, tea preparations, all kinds of fruity preparations (except for children's medications in special cases), oral dosages and oral bubbly agents (except in special cases); 8, other drugs that do not meet the requirements of basic medical insurance.
    In addition, according to the 2020 National Health Insurance Drug Catalog Adjustment Work Programme and the 2020 National Health Insurance Drug Catalog Adjustment Reporting Guidelines, the following seven drugs can be transferred to the health insurance catalog: 1, the treatment of respiratory diseases related to neo-crown pneumonia; 2. Drugs included in the National Essential Medicines Catalog (2018 edition); 3. Included in the list of new drugs in urgent need of overseas medicines in clinical practice, encourage generic drugs catalogue or D encourage research and development to declare the list of children's drugs, and by August 17, 2020 by the State Drug Administration Approved drugs for listing; 4, the second batch of state-organized drugs centralized procurement of selected drugs; 5, January 1, 2015 to August 17, 2020, approved by the State Drug Administration for the listing of new generic drugs; 6, 20 From 1 January 15 to 17 August 2020, according to the results of clinical trials, the State Drug Administration shall apply for and obtain approval for drugs with significant changes in adaptive disorders, functional treatments, etc.; Enter 5 (including) or more provincial-level the latest version of the basic medical insurance drug catalog of drugs.
    With the abolition of local health insurance supplement authority, the normal adjustment of the national version of the medical insurance catalogue has undoubtedly become an important window of opportunity for pharmaceutical companies, this year's medical insurance negotiations will be held in October-November bidding stage, the need for drug companies to focus on.
    .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.